CERDELGA (ELIGLUSTAT)

Cerdelga (Eliglustat) reduces the formation of a certain protein in the body in people with type 1 Gaucher disease.

Gaucher disease is a genetic condition in which the body lacks the enzyme needed to break down certain fatty materials (lipids). Lipids can build up in the body, causing symptoms such as easy bruising or bleeding, weakness, anemia, bone or joint pain, enlarged liver or spleen, or weakened bones that are easily fractured.

Cerdelga (Eliglustat) suppliers in India. Allevaire India New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

The order for Cerdelga (Eliglustat) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

CERDELGA is a glucosylceramide synthase inhibitor indicated for the longterm treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.

Limitation of Use:

CYP2D6 ultra-rapid metabolizers may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect.

A specific dosage cannot be recommended for CYP2D6 indeterminate metabolizers.

Medicine Name: Cerdelga
Generic Name: Eliglustat
Approval Date: Aug 19, 2014

Available as (Form & Strength): 84 mg orally once daily.